We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
+13.19%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$500M
AUM Growth
+$145M
Cap. Flow
+$168M
Cap. Flow %
33.56%
Top 10 Hldgs %
91.39%
Holding
26
New
3
Increased
6
Reduced
11
Closed
5
Avg Time Held Equity + Options
3.6 quarters
Top 10 Avg Time Held Equity + Options
2.1 quarters
Top 20 Avg Time Held Equity + Options
3.5 quarters
Avg Time Held Equity only
3.6 quarters
Top 10 Avg Time Held Equity only
2.1 quarters
Top 20 Avg Time Held Equity only
3.5 quarters

Top Buys

Rank Stock Value
1
CGEM icon
Cullinan Oncology
CGEM
+$89.4M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$59.3M
3
IMA icon
ImageneBio Inc
IMA
+$23.3M
4
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$7.96M
5
ONCR
Oncorus, Inc.
ONCR
+$1.9M

Top Sells

Rank Stock Value
1
AMWL icon
American Well
AMWL
+$6.29M
2
KROS icon
Keros Therapeutics
KROS
+$2.12M
3
OVID icon
Ovid Therapeutics
OVID
+$1.93M
4
DTIL icon
Precision BioSciences
DTIL
+$1.88M
5
INZY icon
Inozyme Pharma
INZY
+$1.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CGEM icon
1
Cullinan Oncology
CGEM
$962M
$91.8M 18.37%
+2,202,407
New +$89.4M
2021 Q1
0 quarters
PLRX icon
2
Pliant Therapeutics
PLRX
$61.1M
$91.4M 18.3%
2,324,795
-30,004
-1% -$974K
2020 Q2
3 quarters
RPTX icon
3
DELISTED
Repare Therapeutics
RPTX
$78.6M 15.73%
2,560,703
+28,553
+1% +$970K
2020 Q2
3 quarters
RXDX
4
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$52.5M 10.51%
+2,874,032
New +$59.3M
2021 Q1
0 quarters
ORTX
5
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$29.4M 5.89%
405,197
+112,078
+38% +$7.96M
2019 Q3
6 quarters
ONCR
6
DELISTED
Oncorus, Inc.
ONCR
$24.7M 4.94%
1,771,786
+91,880
+5% +$1.9M
2020 Q4
1 quarter
KROS icon
7
Keros Therapeutics
KROS
$230M
$24.6M 4.93%
400,468
-33,384
-8% -$2.12M
2020 Q2
3 quarters
IMA icon
8
ImageneBio Inc
IMA
$48.2M
$23M 4.61%
+67,896
New +$23.3M
2021 Q1
0 quarters
LRMR icon
9
Larimar Therapeutics
LRMR
$263M
$22.1M 4.43%
1,515,148
– –
2020 Q2
3 quarters
INZY icon
10
DELISTED
Inozyme Pharma
INZY
$18.4M 3.68%
927,264
-68,132
-7% -$1.5M
2020 Q3
2 quarters
FRLN
11
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$17M 3.41%
92,316
+1,578
+2% +$374K
2020 Q3
2 quarters
AKUS
12
DELISTED
Akouos Inc
AKUS
$11.9M 2.38%
858,027
-12,870
-1% -$234K
2020 Q2
3 quarters
DTIL icon
13
Precision BioSciences
DTIL
$180M
$7.16M 1.43%
23,054
-5,358
-19% -$1.88M
2019 Q3
6 quarters
CRVS icon
14
Corvus Pharmaceuticals
CRVS
$845M
$2.09M 0.42%
679,132
+188,255
+38% +$680K
2019 Q3
6 quarters
GTHX icon
15
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.2M 0.24%
50,000
-12,000
-19% -$279K
2020 Q2
3 quarters
KZR icon
16
DELISTED
Kezar Life Sciences
KZR
$1.04M 0.21%
17,417
+3,917
+29% +$229K
2019 Q3
6 quarters
OVID icon
17
Ovid Therapeutics
OVID
$471M
$995K 0.2%
247,510
-579,750
-70% -$1.93M
2019 Q3
6 quarters
GBT
18
DELISTED
Global Blood Therapeutics, Inc.
GBT
$611K 0.12%
15,000
-7,800
-34% -$359K
2019 Q3
6 quarters
ADVM icon
19
DELISTED
Adverum Biotechnologies
ADVM
$396K 0.08%
4,021
-1,900
-32% -$228K
2020 Q1
4 quarters
BPMC icon
20
DELISTED
Blueprint Medicines
BPMC
$340K 0.07%
3,500
-2,000
-36% -$200K
2019 Q3
6 quarters
RARE icon
21
Ultragenyx Pharmaceutical
RARE
$1.51B
$228K 0.05%
2,000
-1,000
-33% -$136K
2019 Q3
6 quarters
AMWL icon
22
American Well
AMWL
$211M
– –
-12,418
Closed -$6.29M –
BLUE icon
23
DELISTED
bluebird bio
BLUE
– –
-618
Closed -$346K –
DTIL icon
24
CALL
Precision BioSciences
DTIL
$180M
– –
-333
Closed -$8K –
XBI icon
25
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-10,000
Closed -$54K –
1
2

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, CHI Advisors held 26 positions worth $500M, up 41% from $355M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

CHI Advisors deployed $168M of net new capital in Q1 2021, opening 3 new positions and adding to 6 existing holdings. Its largest new stake was Cullinan Oncology: 2,202,407 shares worth $91.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $2.12M trimmed.

  • CHI Advisors's largest Q1 2021 buy was Cullinan Oncology: 2,202,407 shares worth $91.8M.
  • CHI Advisors added most to Orchard Therapeutics plc American Depositary Shares in Q1 2021, an estimated $7.96M increase.
  • CHI Advisors's biggest Q1 2021 reduction was Keros Therapeutics, cutting an estimated $2.12M.
  • CHI Advisors fully exited American Well in Q1 2021, selling an estimated $6.29M.
  • CHI Advisors's ten largest holdings make up 91% of its $500M portfolio in Q1 2021.
  • CHI Advisors opened 3 new positions and closed 5 in Q1 2021.
  • CHI Advisors's portfolio value rose 41% quarter-over-quarter to $500M.

Based on CHI Advisors's 13F filing for Q1 2021, filed 14 May 2021.